Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 - AbCellera Biologics Inc. | d29983dex232.htm |
| S-1/A - AMENDMENT NO. 1 TO FORM S-1 - AbCellera Biologics Inc. | d29983ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
AbCellera Biologics Inc.
We, KPMG LLP, consent to the use of our report, dated October 2, 2020, except for Note 18, as to which the date is November 20, 2020, with respect to the consolidated financial statements of AbCellera Biologics Inc. included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report refers to a change in the method of accounting for leases as of January 1, 2019 due to the adoption of Accounting Standards Codification Topic 842, Leases.
/s/ KPMG LLP
Chartered Professional Accountants
Vancouver, Canada
November 24, 2020